Patents by Inventor Nagakumar Bharatham

Nagakumar Bharatham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11401277
    Abstract: The invention relates to compounds of Formula I and Formula (B) along with their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms, and pharmaceutically active derivatives thereof. These compounds are useful for killing or inhibiting the growth of a microorganism selected from the group consisting of bacteria, virus, fungi, and protozoa.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: August 2, 2022
    Assignee: BUGWORKS RESEARCH, INC.
    Inventors: Shahul Hameed Peer Mohamed, Nagakumar Bharatham, Nainesh Katagihallimath, Sreevalli Sharma, Radha Nandishaiah, Vasanthi Ramachandran
  • Publication number: 20210188777
    Abstract: In one aspect, compounds and compositions that modulate a bromodomain and methods of making and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with inhibition of a bromodomain such as, for example, cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: March 4, 2021
    Publication date: June 24, 2021
    Inventors: R. Kip Guy, P. Jake Slavish, William Robert Shadrick, Brandon M. Young, Vincent A. Boyd, Nagakumar Bharatham, Jeanine E. Price, Anang Shelat
  • Patent number: 11028051
    Abstract: In one aspect, compounds and compositions that modulate a bromodomain and methods of making and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with inhibition of a bromodomain such as, for example, cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: June 8, 2021
    Assignee: St. Jude Children's Research Hospital
    Inventors: R. Kip Guy, P. Jake Slavish, William Robert Shadrick, Brandon M. Young, Vincent A. Boyd, Nagakumar Bharatham, Jeanine E. Price, Anang Shelat
  • Publication number: 20210070772
    Abstract: The invention relates to compounds of Formula I and Formula (B) along with their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms, and pharmaceutically active derivatives thereof. These compounds are useful for killing or inhibiting the growth of a microorganism selected from the group consisting of bacteria, virus, fungi, and protozoa.
    Type: Application
    Filed: November 29, 2018
    Publication date: March 11, 2021
    Inventors: Shahul Hameed PEER MOHAMED, Nagakumar BHARATHAM, Nainesh KATAGIHALLIMATH, Sreevalli SHARMA, Radha NANDISHAIAH, Vasanthi RAMACHANDRAN
  • Patent number: 10912780
    Abstract: The present disclosure relates to compounds of Formula I, or their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof, and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by microbes. The present disclosure also relates to the synthesis and characterization of aforementioned substances.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: February 9, 2021
    Assignee: Bugworks Research, Inc.
    Inventors: Shahul Hameed Peer Mohamed, Nagakumar Bharatham, Nainesh Katagihallimath, Sreevalli Sharma, Radha Nandishaiah, Vasanthi Ramachandran, Balasubramanian Venkataraman
  • Publication number: 20210008078
    Abstract: The present disclosure relates to compounds of Formula I, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention, or suppression of diseases, and conditions mediated by microbes. The present disclosure also relates to the synthesis and characterization of aforementioned substances.
    Type: Application
    Filed: March 28, 2019
    Publication date: January 14, 2021
    Inventors: Shahul Hameed PEER MOHAMED, Nagakumar BHARATHAM, Nainesh KATAGIHALLIMATH, Sreevalli SHARMA, Radha NANDISHAIAH, Vasanthi RAMACHANDRAN
  • Patent number: 10711011
    Abstract: The present disclosure relates to compounds of Formula I, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms thereof and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by microbes. The present disclosure also relates to the synthesis and characterization of aforementioned substances.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: July 14, 2020
    Assignee: BUGWORKS RESEARCH, INC.
    Inventors: Shahul Hameed Peer Mohamed, Nagakumar Bharatham, Nainesh Katagihallimath, Sreevalli Sharma, Radha Nandishaiah
  • Patent number: 10647702
    Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: May 12, 2020
    Assignee: St. Jude Children's Research Hospital
    Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Royappa, Lie Min, Jaeki Min, Antonio Ferreira
  • Publication number: 20200085834
    Abstract: The present disclosure relates to compounds of Formula I, or their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof, and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by microbes. The present disclosure also relates to the synthesis and characterization of aforementioned substances.
    Type: Application
    Filed: June 8, 2018
    Publication date: March 19, 2020
    Inventors: Shahul Hameed PEER MOHAMED, Nagakumar BHARATHAM, Nainesh KATAGIHALLIMATH, Sreevalli SHARMA, Radha NANDISHAIAH, Vasanthi RAMACHANDRAN, Balasubramanian VENKATARAMAN
  • Publication number: 20200079739
    Abstract: In one aspect, compounds and compositions that modulate a bromodomain and methods of making and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with inhibition of a bromodomain such as, for example, cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: December 12, 2017
    Publication date: March 12, 2020
    Inventors: R. Kip Guy, P. Jake Slavish, William Robert Shadrick, Brandon M. Young, Vincent A. Boyd, Nagakumar Bharatham, Jeanine E. Price, Anang Shelat
  • Publication number: 20190345141
    Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: July 23, 2019
    Publication date: November 14, 2019
    Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
  • Publication number: 20190292199
    Abstract: The present disclosure relates to compounds of Formula I, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms thereof and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by microbes. The present disclosure also relates to the synthesis and characterization of aforementioned substances.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 26, 2019
    Inventors: SHAHUL HAMEED PEER MOHAMED, NAGAKUMAR BHARATHAM, NAINESH KATAGIHALLIMATH, SREEVALLI SHARMA, RADHA NANDISHAIAH
  • Publication number: 20180291004
    Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: November 14, 2017
    Publication date: October 11, 2018
    Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
  • Patent number: 9822100
    Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: November 21, 2017
    Assignee: St. Jude Children's Research Hospital
    Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
  • Publication number: 20160297800
    Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: January 8, 2016
    Publication date: October 13, 2016
    Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
  • Patent number: 9266860
    Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: February 23, 2016
    Assignee: St. Jude Children's Research Hospital
    Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Roy-Appa, Lie Min, Jaeki Min, Antonio Ferreira
  • Publication number: 20130345237
    Abstract: The compounds of the invention are antagonists of MDM2 and MDMX, with excellent specificity for MDM2 and MDMX over other proteins, and with selective binding affinity to MDMX over MDM2. The compounds can therefore regulate p53 activity and treat a variety of cancers. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: September 30, 2011
    Publication date: December 26, 2013
    Inventors: R. Kiplin Guy, Yiqun Zhang, Brandon Young, Michael Dyer, Kristin Finch, Donald Bashford, Nagakumar Bharatham, Richard Kriwacki, Grace Royappa, Lie Min, Jaeki Min, Anthony Ferreira